Limits...
Effect of human Wharton's jelly mesenchymal stem cell secretome on proliferation, apoptosis and drug resistance of lung cancer cells.

Hendijani F, Javanmard ShH, Rafiee L, Sadeghi-Aliabadi H - Res Pharm Sci (2015 Mar-Apr)

Bottom Line: Multipotent mesenchymal stem cells (MSCs) are recently found to alter the tumor condition.WJ-MSC secretome neither induced proliferation of lung cancer cells nor affected the apoptotic potential of the tumor cells.Although MSCs did not show antitumor properties, our in vitro results showed that MSC secretome was not tumorigenic and also did not make lung cancer cells resistant to doxorubicin.

View Article: PubMed Central - PubMed

Affiliation: Department of pharmaceutical biotechnology and Isfahan Pharmaceutical Sciences Research Centre, School of pharmacy and pharmaceutical Science, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.

ABSTRACT
Multipotent mesenchymal stem cells (MSCs) are recently found to alter the tumor condition. However their exact role in tumor development is not yet fully unraveled. MSCs were established to perform many of their actions through paracrine effect. Thus investigation of MSC secretome interaction with tumor cells may provide important information for scientists who are attempting to apply stem cells in the treatment of the disease. In this study we investigated the effect of human Wharton's jelly derived MSC (WJ-MSCs) secretome on proliferation, apoptotic potential of A549 lung cancer cells, and their response to the chemotherapeutic agent doxorubicin. WJ-MSCs were isolated from human umbilical cord and then characterized according to the International Society for Cellular Therapy criteria and WJ-MSC secretome was collected. BrdU cell proliferation assay and Annexin V-PI staining were used for the evaluation of cytotoxic and proapoptotic effects of WJ-MSC secretome on A549 cells. WJ-MSC secretome neither induced proliferation of lung cancer cells nor affected the apoptotic potential of the tumor cells. We also studied the combinatorial effect of WJ-MSC secretome and the anticancer drug doxorubicinwhich showed no induction of drug resistance when A549 cells was treated with combination of WJ-MSC secretome and doxorubicin. Although MSCs did not show antitumor properties, our in vitro results showed that MSC secretome was not tumorigenic and also did not make lung cancer cells resistant to doxorubicin. Thus MSC secretome could be considered safe for other medical purposes such as cardiovascular, neurodegenerative, and autoimmune diseases which may exist or occur in cancer patients.

No MeSH data available.


Related in: MedlinePlus

AnnexinV-PI apoptosis assay on A549 cell line treated with hWJ-MSC seretome. There is no significant difference between a; untreated A549, b; A549 treated with hWJ-MSC secretome and c; A549 treated with IFNγ stimulated hWJ-MSC secretome.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4584452&req=5

Figure 5: AnnexinV-PI apoptosis assay on A549 cell line treated with hWJ-MSC seretome. There is no significant difference between a; untreated A549, b; A549 treated with hWJ-MSC secretome and c; A549 treated with IFNγ stimulated hWJ-MSC secretome.

Mentions: Proapototic effect of WJ-MSC secretome on A549 cells was tested by Annexin V-PI staining. Our results showed that there was no significant distinction between treated and untreated groups (Fig. 5). Percent of live cells (lower left in Fig. 5a, b and c) were 98.54% ± 0.56 and 98.89% ± 0.43 in untreated and MSC sec treated groups respectively.


Effect of human Wharton's jelly mesenchymal stem cell secretome on proliferation, apoptosis and drug resistance of lung cancer cells.

Hendijani F, Javanmard ShH, Rafiee L, Sadeghi-Aliabadi H - Res Pharm Sci (2015 Mar-Apr)

AnnexinV-PI apoptosis assay on A549 cell line treated with hWJ-MSC seretome. There is no significant difference between a; untreated A549, b; A549 treated with hWJ-MSC secretome and c; A549 treated with IFNγ stimulated hWJ-MSC secretome.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4584452&req=5

Figure 5: AnnexinV-PI apoptosis assay on A549 cell line treated with hWJ-MSC seretome. There is no significant difference between a; untreated A549, b; A549 treated with hWJ-MSC secretome and c; A549 treated with IFNγ stimulated hWJ-MSC secretome.
Mentions: Proapototic effect of WJ-MSC secretome on A549 cells was tested by Annexin V-PI staining. Our results showed that there was no significant distinction between treated and untreated groups (Fig. 5). Percent of live cells (lower left in Fig. 5a, b and c) were 98.54% ± 0.56 and 98.89% ± 0.43 in untreated and MSC sec treated groups respectively.

Bottom Line: Multipotent mesenchymal stem cells (MSCs) are recently found to alter the tumor condition.WJ-MSC secretome neither induced proliferation of lung cancer cells nor affected the apoptotic potential of the tumor cells.Although MSCs did not show antitumor properties, our in vitro results showed that MSC secretome was not tumorigenic and also did not make lung cancer cells resistant to doxorubicin.

View Article: PubMed Central - PubMed

Affiliation: Department of pharmaceutical biotechnology and Isfahan Pharmaceutical Sciences Research Centre, School of pharmacy and pharmaceutical Science, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.

ABSTRACT
Multipotent mesenchymal stem cells (MSCs) are recently found to alter the tumor condition. However their exact role in tumor development is not yet fully unraveled. MSCs were established to perform many of their actions through paracrine effect. Thus investigation of MSC secretome interaction with tumor cells may provide important information for scientists who are attempting to apply stem cells in the treatment of the disease. In this study we investigated the effect of human Wharton's jelly derived MSC (WJ-MSCs) secretome on proliferation, apoptotic potential of A549 lung cancer cells, and their response to the chemotherapeutic agent doxorubicin. WJ-MSCs were isolated from human umbilical cord and then characterized according to the International Society for Cellular Therapy criteria and WJ-MSC secretome was collected. BrdU cell proliferation assay and Annexin V-PI staining were used for the evaluation of cytotoxic and proapoptotic effects of WJ-MSC secretome on A549 cells. WJ-MSC secretome neither induced proliferation of lung cancer cells nor affected the apoptotic potential of the tumor cells. We also studied the combinatorial effect of WJ-MSC secretome and the anticancer drug doxorubicinwhich showed no induction of drug resistance when A549 cells was treated with combination of WJ-MSC secretome and doxorubicin. Although MSCs did not show antitumor properties, our in vitro results showed that MSC secretome was not tumorigenic and also did not make lung cancer cells resistant to doxorubicin. Thus MSC secretome could be considered safe for other medical purposes such as cardiovascular, neurodegenerative, and autoimmune diseases which may exist or occur in cancer patients.

No MeSH data available.


Related in: MedlinePlus